Related Experiment Video
Updated: Feb 6, 2026

Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection
Published on: January 31, 2020
Long-term treatment gains of a brief exposure-based treatment for PTSD
Johanna Thompson-Hollands1,2, Brian P Marx1,2, Daniel J Lee2
1National Center for PTSD, VA Boston Healthcare System, Boston, Massachusetts.
Background:
Written exposure therapy (WET) is a 5-session PTSD treatment that may address barriers in treatment for posttraumatic stress disorder (PTSD) given its brevity and tolerability. A recent study found outcomes for WET were non-inferior to outcomes from Cognitive Processing Therapy (CPT) through 36 weeks from first treatment session (Sloan, Marx, Lee, & Resick, 2018); the current study examined whether treatment gains were maintained through 60 weeks from first session, and also evaluated both treatments' effect on depressive symptoms.
Methods:
The study enrolled 126 individuals with PTSD randomized to WET or CPT. Assessments were conducted at baseline and 6, 12, 24, 36, and 60 weeks following the first treatment session. PTSD diagnosis and symptom severity were determined via the Clinician Administered PTSD Scale for DSM-5 (CAPS-5), and depression symptoms were assessed using the Beck Depression Inventory-2.
Results:
WET remained non-inferior to CPT through the 60 week assessment; the groups had a difference of less than 3 points in their total CAPS-5 scores, and within-condition effects on PTSD were large (WET d = 1.23; CPT d = 1.38). Both treatments significantly reduced depressive symptoms over the 60 week study, with the CPT group experiencing a more rapid decrease. The between-condition effect of treatment on depression was small (d = .19).
Conclusions:
WET is a treatment that is non-inferior to CPT with regard to PTSD symptoms, with treatment effects that are long-lasting. Additionally, both WET and CPT demonstrated substantial effects on depressive symptoms. WET should be considered a good option for PTSD treatment.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Treatment Resistant Cancers
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Alzheimer's Disease: Treatment
Anticholinesterase Agents: Poisoning and Treatment
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Angle Closure Glaucoma: Treatment

